95 related articles for article (PubMed ID: 11357224)
21. Differentiation and cathepsin D expression in human oral tumors.
Brysk MM; Lei G; Adler-Storthz K; Chen Z; Horikoshi T; Brysk H; Tyring SK; Arany I
Laryngoscope; 1998 Aug; 108(8 Pt 1):1234-7. PubMed ID: 9707250
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of metallothionein and p53 expression as potential prognostic markers for laryngeal squamous cell carcinoma.
Brown JJ; Xu H; William-Smith L; Mohamed H; Teklehaimanot S; Zhuo J; Osborne R; Liu F; Gowans RE; Nishitani J; Liu X
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL473-9. PubMed ID: 14995078
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer.
Ozer E; Mungan MU; Tuna B; Kazimoğlu H; Yörükoğlu K; Kirkali Z
Urology; 1999 Jul; 54(1):50-5. PubMed ID: 10414726
[TBL] [Abstract][Full Text] [Related]
25. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer.
Vigneswaran N; Zhao W; Dassanayake A; Muller S; Miller DM; Zacharias W
Hum Pathol; 2000 Aug; 31(8):931-7. PubMed ID: 10987253
[TBL] [Abstract][Full Text] [Related]
26. Prognostic evaluation of metallothionein expression in human colorectal neoplasms.
Ioachim EE; Goussia AC; Agnantis NJ; Machera M; Tsianos EV; Kappas AM
J Clin Pathol; 1999 Dec; 52(12):876-9. PubMed ID: 10711249
[TBL] [Abstract][Full Text] [Related]
27. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
28. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas.
Cao XL; Xu RJ; Zheng YY; Liu J; Teng YS; Li Y; Zhu J
Asian Pac J Cancer Prev; 2011; 12(12):3245-9. PubMed ID: 22471461
[TBL] [Abstract][Full Text] [Related]
29. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
30. Squamous cell carcinoma of the vulva. Expression of tumor proteases cathepsin-D and pro-cathepsin-L.
Hantschmann P; Beysiegel S; Kurzl R
J Reprod Med; 1998 Nov; 43(11):933-42. PubMed ID: 9839260
[TBL] [Abstract][Full Text] [Related]
31. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
32. Protein expression of MMP-2 and MT1-MMP in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma.
de Oliveira Poswar F; de Carvalho Fraga CA; Gomes ES; Farias LC; Souza LW; Santos SH; Gomez RS; de-Paula AM; Guimarães AL
Int J Surg Pathol; 2015 Feb; 23(1):20-5. PubMed ID: 24984957
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical localization of cathepsin L and cystatin A in normal skin and skin tumors.
Palungwachira P; Kakuta M; Yamazaki M; Yaguchi H; Tsuboi R; Takamori K; Ogawa H
J Dermatol; 2002 Sep; 29(9):573-9. PubMed ID: 12392065
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of cathepsin L and its inhibitor headpin in oral squamous cell carcinoma.
Nakashima T; Yasumatsu R; Masuda M; Clayman GL; Komune S
J Laryngol Otol; 2012 Nov; 126(11):1134-7. PubMed ID: 22963824
[TBL] [Abstract][Full Text] [Related]
35. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.
Leusink FK; Koudounarakis E; Frank MH; Koole R; van Diest PJ; Willems SM
BMC Cancer; 2018 Apr; 18(1):385. PubMed ID: 29618339
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.
Charpin C; Garcia S; Bouvier C; Martini F; Lavaut M; Allasia C; Bonnier P; Andrac L
J Clin Pathol; 1997 Jul; 50(7):586-90. PubMed ID: 9306940
[TBL] [Abstract][Full Text] [Related]
39. Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L.
Fröhlich E; Möhrle M; Klessen C
Arch Dermatol Res; 2004 Mar; 295(10):411-21. PubMed ID: 14767779
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of Ki-67 and p53 immunoreactivity in cutaneous squamous cell carcinomas.
Mansoor A; McKee PH; Simpson JA; McGuire B; Hobbs C
Am J Dermatopathol; 1996 Aug; 18(4):351-7. PubMed ID: 8879297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
